Skip to main content
Evidence Based Longevity (EBL)Check what I take
← All protocols
C

Protocol

Two green kiwifruit a day for constipation

In a randomized crossover A trial design in which each participant receives both the treatment and the comparison, one after the other, and serves as their own control. trial of 184 people, two green kiwifruit a day for 4 weeks increased complete bowel movements by about 1.5 a week in functional constipation and constipation-predominant IBS, compared with baseline, with better gut comfort; the comparison treatment was psyllium.

Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →

Compare this record with another, side by side →

At a glance

In plain words

Two green kiwifruit a day for four weeks gave people with constipation about one and a half more full bowel movements a week and less discomfort. The main trial compared kiwifruit with a fiber supplement. A kiwifruit company sponsored the main trial.

The letter, taken apart
What was measured
The number of complete bowel movements per week, from diaries over 4 weeks.
How big
About 1.5 more complete bowel movements a week in functional constipation and IBS-C.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 36537785.
Who it applies to
Adults with functional constipation or IBS-C.
Safety
No serious side effects were reported.
The record in one view
Compared with
Psyllium fiber 7.5 g a day, in crossover.
Certainty
Grade C, resting on: One randomized crossover trial and one exploratory partially randomized trial.
What would change this grade
Could rise to B with: Randomized trial of kiwifruit against a placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received. food. Who: Adults with chronic constipation. Measured: Complete spontaneous bowel movements per week. Length: At least 4 weeks.
Cost
No price recorded yet.
Sources
2 studies cited on this record, listed under Sources.
For clinicians
A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
Food
CSelf-report Grade C

In a randomized crossover trial of 184 people, two green kiwifruit a day for 4 weeks increased complete bowel movements by about 1.5 a week in functional constipation and constipation-predominant IBS, compared with baseline, with better gut comfort; the comparison treatment was psyllium. A second US trial was only partly randomized and exploratory, so the result stands as one trial and the letter is C.

Why this letter

Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Why this grade

Grade C on bowel movements in constipation. One randomized crossover trial of 184 people found about 1.5 more complete bowel movements a week from baseline with two kiwifruit daily (Gearry et al., 2023; PMID 36537785).

WHY NOT Bthe supporting US trial was partly randomized and explicitly exploratory (Chey et al., 2021; PMID 34074830), so the result has no independent replication The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away.; the endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. is self-reported from bowel diaries, and the comparator was psyllium, not a placebo. FUNDING: the main trial was sponsored and funded by Zespri International, a kiwifruit marketer, which reviewed and approved the study design.

WHAT THIS GRADE DOES NOT COVERgold kiwifruit, kiwifruit extracts and powders, and constipation caused by medicines, none of which this trial tested.

A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →

Who responds: this record's trial reading reports no subgroup that identifies who responds.

Evidence notes: randomized trial

Endpoint graded: Number of complete spontaneous bowel movements per week (self_report)

Last reviewed: November 2026

Evidence wanted

The trial that would change this grade.

DesignRandomized trial of kiwifruit against a placebo food
PopulationAdults with chronic constipation
EndpointComplete spontaneous bowel movements per week
DurationAt least 4 weeks

A positive trial of this shape, supported by further trials, would move this entry to B.

Why the current trials fall short

An independent, fully randomized replication would carry the letter to B.

Clinical trials

ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Kiwifruit among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.

Search recruiting studies of Kiwifruit on ClinicalTrials.gov

Dose, form and timing

What to track

The number of complete bowel movements per week, and straining.

Safety

Safety evidence, by strength

No safety data. Each caution on this record, sorted by what it rests on.

Documented in human studies
Cautions resting on what randomized trials or large studies found in people.

None recorded.

Suspected from case reports
Harms reported in individual patients or uncontrolled observations, not confirmed by a trial.

None recorded.

Mechanistic only
Cautions reasoned from how it works, with no human harm data behind them.

None recorded.

Population cautions
Groups in whom it has not been studied, so its safety there is unknown.

None recorded.

No safety data

No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.

Grade history

How this letter has changedLatest: No. 444 · November 2026 · First graded.
Grade history
No. 444 · November 2026 · First graded
Two green kiwifruit a day for constipation enters the food section: Grade C

New record in the food section. In a randomized crossover trial of 184 people, two green kiwifruit a day for 4 weeks increased complete bowel movements by about 1.5 a week in functional constipation and constipation-predominant IBS, compared with baseline, with better gut comfort; the comparison treatment was psyllium. A second US trial was only partly randomized and exploratory, so the result stands as one trial and the letter is C.PMID 36537785 PMID 34074830

Every change to a letter on this site is dated and published. The full evidence log →

Sources

How this record was checked
Citations
Every paper cited on this page is matched to its PubMed record on every build.
Retractions
None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
Read against the papers
November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
Outside review
Not yet done. No reviewer outside EBL has checked this record.

What each of these checks can and cannot show: evidence integrity.

The evidence, in fullTwo papers, each linked to its PubMed record.
The evidence

Gearry et al. (Am J Gastroenterol, 2023; PMID 36537785): randomized AB/BA crossover trial, 184 participants (63 healthy, 60 functional constipation, 61 IBS-C), 2 green kiwifruit or psyllium 7.5 g daily for 4 weeks each; kiwifruit increased complete spontaneous bowel movements by 1.53 per week in functional constipation and 1.73 in IBS-C from baseline and improved GI comfort. Chey et al. (Am J Gastroenterol, 2021; PMID 34074830): exploratory partially randomized trial, 79 US patients with chronic constipation; kiwifruit, prunes and psyllium all increased bowel movements; kiwifruit had the fewest adverse events.

How EBL searched for the trials (1 search)

The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.

Searched PubMed in November 2026. 12 records screened, 2 eligible for the graded claim.
Query: (kiwifruit[tiab] OR kiwi[tiab]) AND (constipation[tiab] OR bowel[tiab]) AND randomized controlled trial[pt]
All 12 records screened by title. A 2022 randomized trial of gold (not green) kiwifruit (PMID 36235798) and extract trials test different products and do not replicate the green kiwifruit result.
PubMed watch: does a new study change the grade? (nothing new)

No new paper matching the search behind this grade has been added to PubMed since November 2026.

Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.

Who paid for these trials

For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.

  • Gearry et al., 2023, Am J Gastroenterol (PMID 36537785): PubMed lists no funder for this trial. The PubMed record carries a competing-interest statement.
  • Chey et al., 2021, Am J Gastroenterol (PMID 34074830): PubMed lists no funder for this trial.

Disclosure

Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.

Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy

© Evidence Based Longevity, Inc. All rights reserved

Medical disclaimer

These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.

Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →

Build 9b19d78, November 2026